Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression

Journal of Neuropathology and Experimental Neurology

Volumn 56, Issue 8, 1997, Pages 901-911

  Li, Shi ^c   Mallory, Margaret ^a   Alford, Michael ^a   Tanaka, Seigo ^a   Masliah, Eliezer ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c San Diego ^*

Author keywords

Alzheimer disease; Areyield precursor protein; Excitetoxicity; Glutamate transporter; Neurodegeneration

Indexed keywords

AMYLOID PRECURSOR PROTEIN; EXCITATORY AMINO ACID; GLUTAMIC ACID; MESSENGER RNA; POLYCLONAL ANTIBODY;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; FRONTAL CORTEX; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; NEUROPATHOLOGY; NEUROTRANSMISSION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS;

EID: 0030872412     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005072-199708000-00008     Document Type: Article

References (51)

1. Greenamyre JT, Porter RHP. Anatomy and physiology of glutamate in the CNS. Neurology 1994;44(suppl):S7-13
2. Kanai Y, Smith CR Hediger MA. The elusive transporters with a high affinity for glutamate. Trends Neurosci 1993;16:359-65
3. Balcar VJ, Li Y. Heterogeneity of high affinity uptake of L-glutamate and L-aspartate in the mammalian central nervous system. Life Sci 1992;51:1467-78
4. Storck T, Schulte S, Hofman K, Stoffel W. Structure, expression, and functional analysis of a Na+-dependent glutamate/aspartate transporter from rat brain. Proc Natl Acad Sci USA 1992;89: 10955-59
5. Pines G, Danbolt NC, Bjoras M, Zhang Y, Bendahan A, Eide L, Koepsell H, Storm-Mathisen J, Seeberg E, Kanner BI. Cloning and expression of a rat brain L-glutamate transporter. Nature 1992; 360:464-67
6. Kanai Y, Hediger MA. Primary structure and functional characterization of a high-affinity glutamate transporter. Nature 1992;360: 467-71
7. Kanai Y, Nussberger S, Romero MF, Boron WF, Hebert SC, Hediger MA. Electrogenic properties of the epithelial and neuronal high affinity glutamate transporter. J Biol Chem 1995;270:16561-68
8. Rothstein JD, Martin L, Levey AI, Dykes-Hoberg M, Kuncl RW. Localization of neuronal and glial glutamate transporters. Neuron 1994;13:713-25
9. Rothstein JD, Jin L, Dykes-Hoberg M, Kuncl RW. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci USA 1993;90:6591-95
10. Rothstein JD, Dykes-Hoberg M, Pardo CA, et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 1996;16:675-86
11. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW. Selective loss of glial glutamate trasporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;38:73-84
12. Scott HL, Tannenberg AEG, Dodd PR. Variant forms of neuronal glutamate trasporter sites in Alzheimer's disease cerebral cortex. J Neurochem 1995;64:2193-2202
13. Cowburn R, Hardy J, Roberts P, Briggs R. Presynaptic and postsynaptic glutamatergic function in Alzheimer's disease. Neurosci Lett 1988;86:109-13
14. Cowburn RF, Hardy JA, Roberts PJ. Glutamatergic neurotransmission in Alzheimer's disease. Biochem Soc Trans 1990;18:390-92
15. Masliah E, Alford M, Salmon D, DeTeresa R, Mallory M, Hansen L. Deficient glutamate transporter activity in Alzheimer's disease is associated with accumulation of brain spectrin degradation products and neurodegeneration. Ann Neurol 1997;40:759-66
16. Mattson MP, Cheng B, Culwell AR, Esch FS, Lieberburg I, Rydel RE. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the ß-amyloid precursor protein. Neuron 1993;10:243-54
17. Mucke L, Abraham CR, Ruppe MD, Rockenstein EM, Toggas SM, Alford M, Masliah E. Protection against HIV-1 gp120-induced brain damage by neuronal overexpression of human amyloid precursor protein (hAPP). J Exp Med 1995;181:1551-56
18. Masliah E. Mechanisms of synaptic dysfunction in Alzheimer's disease. Histol Histopathol 1995;10:509-19
19. Mattson MP, Cheng B, Smith-Swintosky VL. Mechanisms of neurotrophic factor protection against calcium-and free radical-mediated excitotoxic injury: Implications for treating neurodegenerative disorders. Exp Neurol 1993;124:89-95
20. Mattson MP, Tomaselli KJ, Rydel RE. Calcium-destabilizing and neurodegenerative effects of aggregated β-amyloid peptide are attenuated by basic FGF. Brain Res 1993;621:35-49
21. Furukawa K, Barger SW, Blalock E, Mattson MP. Activation of K+ channels and suppression of neural activity by secreted β-amyloid precursor protein. Nature 1996;379:74-78
22. Masliah E, Raber J, Alford M, Mallory M, Mattson MP, Westland CE, Mucke L. Amyloid protein precursor stimulates excitatory amino acid transport: Possible involvement in neuroprotective in vivo functions. J Biol Chem 1997. Forthcoming.
23. Rockenstein EM, McConlogue L, Tan H, Power M, Masliah E, Mucke L. Levels and alternative splicing of amyloid β protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease. J Biol Chem 1995;270:28257-67
24. Terry RD, Peck A, DeTeresa R, Schechter R, Horoupian DS. Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann Neurol 1981;10:184-92
25. Wiedenmann B, Franke WW. Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic of presynaptic vesicles. Cell 1985;41:1017-28
26. Masliah E, Terry RD, Alford M, DeTeresa RM, Hansen LA. Cortical and subcortical patterns of synaptophysin-like immunoreactivity in Alzheimer disease. Am J Pathol 1991;138:235-46
27. Mucke L, Masliah E, Johnson WB, et al. Synaptotrophic effects of human amyloid β protein precursors in the cortex of transgenic mice. Brain Res 1994;666:151-67
28. Alford MF, Masliah E, Hansen LA, Terry RD. A simple dot-immunobinding assay for the quantification of synaptophysin-like immunoreactivity in human brain. J Histochem Cytochem 1994;42: 283-87
29. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with Folin phenol reagent. Biol Chem 1951;193:265-72
30. Buxbaum JD, Gandy SE, Cicchetti P, et al. Processing of Alzheimer β /A4 amyloid precursor protein: Modulation by agents that regulate protein phosphorylation. Proc Natl Acad Sci USA 1990;87: 6003-36
31. Masliah E, Mallory M, Hansen L, DeTeresa R, Alford M, Terry R. Synaptic and neuritic alterations during the progression of Alzheimer's disease. Neurosci Lett 1994;174:67-72
32. Masliah E, Fagan AM, Terry RD, DeTeresa R, Mallory M, Gage FH. Reactive synaptogenesis assessed by synaptophysin immunoreactivity is associated with GAP-43 in the dentate gyrus of the adult rat. Exp Neurol 1991;113:131-42
33. Toggas SM, Masliah E, Rockenstein EM, Mucke L. Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 1994;367:188-93
34. Iwai A, Masliah E, Sundsmo MP, DeTeresa R, Mallory M, Salmon DP, Saitoh T. The synaptic protein NACP is abnormally expressed during the progression of Alzheimer's disease. Brain Res 1996;720: 230-34
35. 3H]d-aspartate binding and high-affinity glutamate uptake in the human brain. Neurosci Lett 1986;63:121-24
36. 3H]asparate binding in Down's syndrome brains. Brain Res 1989;484:273-78
37. 3H]TCP binding sites in Alzheimer's disease brains. Brain Res 1988;462:76-82
38. Dickson DW, Farlo J, Davies P, Crystal H, Fuld P, Yen SC. Alzheimer disease. A double immunohistochemical study of senile plaques. Am J Pathol 1988;132:86-101
39. Lynch G, Baudry M. Brain spectrin, calpain and long term changes in synaptic efficacy. Brain Res Bull 1987;18:809-15
40. Seubert P, Ivy G, Larson J, Lee J, Shahi K, Baudry M, Lynch G. Lesions of entorhinal cortex produce a calpain-mediated degradation of brain spectrin in dentate gyrus. I. Biochemical studies. Brain Res 1988;459:226-32
41. Lowy MT, Wittwnberg L, Yamamoto BK. Effect of acute stress on hippocampal glutamate levels and spectrin proteolysis in young and aged rats. J Neurochem 1995;65:268-74
42. Broroson JR, Marcuccilli CJ, Miller RJ. Delayed antagonism of calpain reduces excitotoxicity in cultured neurons. Stroke 1995; 26:1259-67
43. Bristol LA, Rothstein JD. Glutamate trasporter gene expression in amyotrophic lateral sclerosis motor cortex. Ann Neurol 1996;39: 676-79
44. Casado M, Bendahan A, Zafra F, Danbolt NC, Aragon C, Gimenez C, Kanner BI. Phosphorylation and modulation of brain glutamate transporters by protein kinase C. J Biol Chem 1993;268:27313-17
45. Masliah E, Westland CE, Abraham CR, Mallory M, Veinbergs I, Rockenstein EM, Mucke L. Amyloid precursor protein protects neurons of transgenic mice against acute and chronic excitotoxic injuries in vivo. Neurosci 1997;78:135-41
46. +-dependent glutamate uptake in rat hippocampal astrocyte cultures. J Neurochem 1996;67:277-86
47. Weiss JH, Pike CJ, Cotman CW. Ca2+ channel blockers attenuate beta-amyloid peptide toxicity to cortical neurons in culture. J Neurochem 1994;62:372-75
48. Selkoe DJ. Physiological production of the β-amyloid protein and the mechanisms of Alzheimer's disease. Trends Neurosci 1993;16: 403-9
49. Seubert P, Vigo-Pelfrey C, Esch F, et al. Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids. Nature 1992;359:325-27
50. Saitoh T, Kang D, Mallory M, DeTeresa R, Masliah E. Glial cells in Alzheimer's disease: Preferential effect of APOE risk on scattered microglia. Gerontology 1997;43:109-18
51. Furukawa K, Sopher BL, Rydel RE, Begley JG, Pham DG, Martin GM, Fox M, Mattson MP. Increased activity regulating and neuroprotective efficacy of α-secretase-derived secreted amyloid precursor protein conferred by a c-terminal heparin-binding domain. J Neurochem 1996;67:1882-92